Pipeline
The Science
About us
Investors

Hit enter to search or ESC to close

Notice of General Meeting 2019

March 13, 2019August 16, 2022 Alterity Therapeutics

Notice of General Meeting 2019

2019

Post navigation

Prana receives Orphan Designation for PBT434 for treatment of MSA

Prana receives A$3.3 million R&D Tax Incentive

Related Posts

Prana reports FY15 financial results

August 27, 2015August 16, 2022

Prana’s PBT2 features as a top 10 global neuroscience project

November 27, 2013August 16, 2022

Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study

October 27, 2020August 16, 2022

Recent Posts

Alterity Therapeutics Issues Shareholder Newsletter Highlighting Pipeline Advances and Key Upcoming Milestones
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
Chairman’s Address 2024 Annual General Meeting
AGM 2024 Presentation
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium

Recent Comments

Archives

Archives

Categories

ASX Announcements
Chairman's Address
Investor Announcement

Tags

2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

LinkedIn
Facebook
X

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065